← Leaderboards
Jarvis Thale
Crestone, Inc.
$5,951,244
Attributed
$5,951,244
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.6M · FY2015–19$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$5,951,244 · 1
By mechanism
N01$5,951,244 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Series”
- Lawrence Corey · Fred Hutchinson Cancer Center$445,660,381
- Kiran Datta · Leidos Biomedical Research, Inc.$292,634,066
- David R. Weir · University Of Michigan At Ann Arbor$276,156,779
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$231,733,045
- Dennis R. Burton · Scripps Research Institute$199,946,411
- Joel A Lipkin · Four Points Technology, Llc$183,862,844
Research focus
SeriesGram-Positive BacteriaCommunicable DiseasesLeadDrug CandidateFuturePharmaceutical ChemistryPre-ClinicalSmall MoleculeTherapeutic DevelopmentInfectious Disease TreatmentToxic EffectIn VitroStaphylococcus AureusStreptococcus PneumoniaeStreptococcus PyogenesBacillus AnthracisMacrolide-ResistancePenicillin ResistanceVancomycin Resistant EnterococcusMethicillin Resistant Staphylococcus AureusClinical DevelopmentIn VivoIn Vivo Evaluation
Grant awards (4)
Optimizing Lead Therapeutic Compounds Against Infectious Diseases$81,740
N01 · FY2019 · AI · contact PI
Optimizing Lead Therapeutic Compounds Against Infectious Diseases$2,575,997
N01 · FY2018 · AI · contact PI
Optimizing Lead Therapeutic Compounds Against Infectious Diseases$1,507,181
N01 · FY2016 · AI · contact PI
Optimizing Lead Therapeutic Compounds Against Infectious Diseases$1,786,326
N01 · FY2015 · AI · contact PI